Ticagrelor for preventing atherothrombotic events after myocardial infarction

1 Recommendations 1.1 Ticagrelor, in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event. Treatment should be stopped when clinically indicated or at a maximum of 3 years. 2 The technology Summary of ticagrelor Ticagrelor (Brilique, AstraZeneca) is an oral antagonist of the P2Y12 Description of the adenosine diphosphate receptor that inhibits platelet aggregation and technology thrombus formation in atherosclerotic disease. Ticagrelor 60 mg twice daily, co-administered with aspirin (acetylsalicylic acid), has a marketing authorisation for 'the prevention of atherothrombotic events in adult patients with a history of myocardial infarction of at least 1 year and a high risk of developing an atherothrombotic event'. The marketing authorisation for preventing atherothrombotic events in Marketing authorisation adults with a history of myocardial infarction and a high risk of an atherothrombotic event was granted in February 2016. NICE's technology appraisal guidance on ticagrelor for the treatment of acute coronary syndromes covers ticagrelor 90 mg and aspirin for preventing atherothrombotic events. Ticagrelor is contraindicated in patients with active pathological bleeding, a history of intracranial haemorrhage, or severe hepatic impairment. Co-administration
